Effects of General Anaesthetic Agents on the Efficacy of Electroconvulsive Therapy and EEG Changes in Patients with Depression
Key facts
- Where
- Turku, FinnországSee the site
- Phase
- 4. fázis
Where in Finnország
- Varsinais-Suomen hyvinvointialueTurku, FinnországToborzás még nem indult
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Varsinais-Suomen hyvinvointialue
- Trial code
- EU 2025-524829-40-00
- Record updated
- 2026. október 7.
- Original description
The primary objective of the study is to determine whether the choice of anaesthetic agent (methohexital, propofol, or etomidate) influences the speed of clinical response to ECT during the treatment course measured by Montgomery-Åsberg depression scale (MARDS).Read full original descriptionShow less
The primary objective of the study is to determine whether the choice of anaesthetic agent (methohexital, propofol, or etomidate) influences the speed of clinical response to ECT during the treatment course measured by Montgomery-Åsberg depression scale (MARDS).
Inclusion: Written informed consent obtained prior to study procedures 2. Age 18–75 years 3. Diagnosis of severe unipolar depression requiring ECT (ICD-10: F32.1x, F32.2x, F32.3, F33.1x, F33.2x, F33.3) 4. Considered suitable for ECT by the treating psychiatrist 5. Patients undergoing their first acute course of ECT 6. Able to comply with study procedures and the scheduled ECT treatment series 7. ASA Physical status I-III.
Exclusion: Left-handedness 2. Personality disorder or active substance use disorder 3. Pregnancy or breastfeeding 4. Any degree of legal incapacity to provide legal consent 5. Patients receiving involuntary psychiatric treatment 6. Contraindications to study anaesthetic agents or neuromuscular blockers 7. Severe obesity (BMI > 45) 8. Epilepsy or use of antiepileptic medication for any reason (e.g., neuropathic pain) 9. Bipolar disorder (F31.x) 10. Non-affective psychotic disorders (F20–F29) 11. Clinically significant neurological disorders that are considered likely to interfere with EEG interpretation, seizure physiology, or the scientific validity of the study outcomes.